Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Medknow in Medical Gas Research
- Vol. 10 (2) , 75-80
Abstract
Chemotherapy, targeted therapy, and immunotherapy are used against advanced non-small cell lung cancer. A clinically efficacious method for relieving the adverse events associated of such therapies is lacking. Fifty-eight adult patients were enrolled in our trial to relieve pulmonary symptoms or the adverse events of drugs. Twenty patients who refused drug treatment were assigned equally and randomly to a hydrogen (H2)-only group and a control group. According to the results of tumor-gene mutations and drug-sensitivity tests, 10, 18, and 10 patients were enrolled into chemotherapy, targeted therapy, and immunotherapy groups in which these therapies were combined with H2-therapy, respectively. Patients underwent H2 inhalation for 4–5 hours per day for 5 months or stopped when cancer recurrence. Before study initiation, the demographics (except for tumor-mutation genes) and pulmonary symptoms (except for moderate cough) of the five groups showed no significant difference. During the first 5 months of treatment, the prevalence of symptoms of the control group increased gradually, whereas that of the four treatment groups decreased gradually. After 16 months of follow-up, progression-free survival of the control group was lower than that of the H2-only group, and significantly lower than that of H2 + chemotherapy, H2 + targeted therapy, and H2 + immunotherapy groups. In the combined-therapy groups, most drug-associated adverse events decreased gradually or even disappeared. H2 inhalation was first discovered in the clinic that can be used to control tumor progression and alleviate the adverse events of medications for patients with advanced non-small cell lung cancer. This study was approved by the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval No. Fuda20181207), and was registered at ClinicalTrials.gov (Identifier: NCT03818347) on January 28, 2019.Keywords
This publication has 56 references indexed in Scilit:
- Protective effects of hydrogen enriched saline on liver ischemia reperfusion injury by reducing oxidative stress and HMGB1 releaseBMC Gastroenterology, 2014
- Therapeutic Effects of Hydrogen-Rich Solution on Aplastic Anemia in VivoCellular Physiology and Biochemistry, 2013
- The evolution of molecular hydrogen: a noteworthy potential therapy with clinical significanceMedical Gas Research, 2013
- Hydrogen‐rich water attenuates experimental periodontitis in a rat modelJournal of Clinical Periodontology, 2011
- Hydrogen-Rich Saline Protects Against Acute Lung Injury Induced by Extensive Burn in Rat ModelJournal of Burn Care & Research, 2011
- Consumption of Hydrogen Water Reduces Paraquat‐Induced Acute Lung Injury in RatsBioMed Research International, 2011
- Impaired lymphocyte mitochondrial antioxidant defences in variegate porphyria are accompanied by more inducible reactive oxygen species production and DNA damageBritish Journal of Haematology, 2010
- Hydrogen in Drinking Water Reduces Dopaminergic Neuronal Loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Parkinson's DiseasePLOS ONE, 2009
- Hydrogen-rich saline protects against intestinal ischemia/reperfusion injury in ratsFree Radical Research, 2009
- Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stressBiochemical and Biophysical Research Communications, 2007